19.88
price up icon13.41%   2.35
after-market Dopo l'orario di chiusura: 20.14 0.26 +1.31%
loading
Precedente Chiudi:
$17.53
Aprire:
$17.66
Volume 24 ore:
3.99M
Relative Volume:
1.81
Capitalizzazione di mercato:
$1.82B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-10.98
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
+18.62%
1M Prestazione:
+22.79%
6M Prestazione:
-19.51%
1 anno Prestazione:
-11.92%
Intervallo 1D:
Value
$17.66
$20.14
Intervallo di 1 settimana:
Value
$16.49
$20.14
Portata 52W:
Value
$13.53
$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name
Nome
Beam Therapeutics Inc
Name
Telefono
857-327-8775
Name
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Dipendente
502
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
BEAM's Discussions on Twitter

Confronta BEAM con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BEAM
Beam Therapeutics Inc
19.88 1.82B 352.57M -143.01M -153.40M -1.81
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-28 Aggiornamento BofA Securities Neutral → Buy
2025-03-10 Aggiornamento Scotiabank Sector Perform → Sector Outperform
2025-01-29 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2024-11-06 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-07-23 Iniziato H.C. Wainwright Buy
2024-01-29 Aggiornamento JP Morgan Neutral → Overweight
2023-12-15 Downgrade BofA Securities Buy → Neutral
2023-12-08 Downgrade Jefferies Buy → Hold
2023-10-20 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-10-20 Downgrade Leerink Partners Outperform → Market Perform
2023-03-21 Iniziato Bernstein Mkt Perform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2022-12-20 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-12-13 Iniziato Citigroup Buy
2022-06-17 Iniziato BMO Capital Markets Market Perform
2022-04-28 Iniziato Credit Suisse Neutral
2022-01-05 Iniziato Guggenheim Buy
2021-10-19 Iniziato SVB Leerink Outperform
2021-09-24 Ripresa Stifel Buy
2021-09-10 Iniziato BofA Securities Buy
2021-05-11 Iniziato Redburn Buy
2021-05-04 Iniziato RBC Capital Mkts Sector Perform
2021-03-01 Downgrade Barclays Overweight → Equal Weight
2021-02-16 Iniziato Wells Fargo Overweight
2021-01-29 Downgrade JP Morgan Overweight → Neutral
2021-01-06 Iniziato Stifel Hold
2020-08-05 Iniziato William Blair Outperform
2020-03-02 Iniziato Barclays Overweight
2020-03-02 Iniziato JP Morgan Overweight
2020-03-02 Iniziato Jefferies Buy
2020-03-02 Iniziato Wedbush Outperform
Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

pulisher
Jun 18, 2025

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

BEAM Therapeutics’ SWOT analysis: base editing pioneer’s stock faces pivotal year - Investing.com

Jun 17, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 16, 2025
pulisher
Jun 16, 2025

H.C. Wainwright reiterates buy rating on Beam Therapeutics stock - Investing.com

Jun 16, 2025
pulisher
Jun 14, 2025

Cathie Wood’s ARK ETFs adjust holdings, buying GitLab and Beam Therapeutics stock - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clini - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Announces New Data from BEACON Phase 1/2 - GlobeNewswire

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics (BEAM) Reports Strong Results for Sickle Cell Therapy - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Beam reports positive results from sickle cell disease treatment - Seeking Alpha

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics reports positive data from sickle cell therapy trial - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics reports positive data from sickle cell therapy trial By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

Beam Therapeutics (BEAM) Releases Promising Data from BEACON Trial | BEAM Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

New Clinical Data: BEAM's Sickle Cell Gene Therapy Achieves Remarkable 60%+ Success Metric in All Patients - Stock Titan

Jun 13, 2025
pulisher
Jun 11, 2025

Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

ARK Investment Acquires 349K Shares of Beam Therapeutics (BEAM) | BEAM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Tesla’s Driverless Robotaxis Are Operating On Texas Streets - The Globe and Mail

Jun 11, 2025
pulisher
Jun 06, 2025

Beam Therapeutics Confirms Key Decisions at Annual Meeting - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Beam Therapeutics Announces Pricing of Underwritten Offering - Revista ADVFN

Jun 06, 2025
pulisher
Jun 05, 2025

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - mx.advfn.com

Jun 05, 2025
pulisher
Jun 04, 2025

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - The Globe and Mail

Jun 04, 2025
pulisher
Jun 04, 2025

BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates - The Globe and Mail

Jun 04, 2025
pulisher
Jun 03, 2025

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - mx.advfn.com

Jun 03, 2025
pulisher
Jun 03, 2025

Beam gets FDA orphan drug status for sickle cell disease treatment - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Says Potential Sickle Cell Therapy Receives FDA Orphan Drug Designation - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics (BEAM) Gains FDA Orphan Drug Status for Sickle - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics’ BEAM-101 receives FDA orphan drug status for SCD treatment - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Gra - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - Yahoo Finance

Jun 03, 2025
pulisher
Jun 01, 2025

Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io

Jun 01, 2025
pulisher
May 31, 2025

Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com

May 31, 2025
pulisher
May 30, 2025

Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 29, 2025

FDA Grants Orphan Drug Status to Beam Therapeutics Inc. (BEAM)’ AATD Gene Therapy - Insider Monkey

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics’ BEAM-302 gains FDA orphan drug status for AATD treatment - Investing.com India

May 29, 2025
pulisher
May 29, 2025

FDA Grants Orphan Drug Status to Beam Therapeutics' (BEAM) BEAM-302 | BEAM Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Beam receives Orphan Drug status for genetic disorder asset BEAM-302 - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD) - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics Scores Dual FDA Wins as Orphan Drug Status Follows Promising AATD Trial Results - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Beam Therapeutics: A Cautious Hold On A Base Editing Pioneer (NASDAQ:BEAM) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now - simplywall.st

May 29, 2025
pulisher
May 28, 2025

Beam Therapeutics (BEAM) Secures FDA Orphan Designation for New - GuruFocus

May 28, 2025

Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Beam Therapeutics Inc Azioni (BEAM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Evans John M.
CEO
Apr 01 '25
Sale
18.35
30,663
562,684
986,249
Ciaramella Giuseppe
President
Apr 01 '25
Sale
18.35
7,434
136,418
190,216
Cavanagh Bethany J
SVP, Finance and Treasurer
Apr 01 '25
Sale
18.35
3,015
55,330
44,512
Simon Amy
Chief Medical Officer
Apr 02 '25
Sale
17.73
20,997
372,294
65,742
Simon Amy
Chief Medical Officer
Apr 01 '25
Sale
18.35
9,566
175,542
86,739
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):